|NASDAQ: BIIB||Healthcare / Drug Manufacturers / USA|
|270.03||+4.86||+1.83%||Vol 968.18K||1Y Perf 24.49%|
|Mar 24th, 2023 16:00 DELAYED|
|- -||0.12 0.04%|
|Target Price||308.58||Analyst Rating||Moderate Buy 1.74|
|Potential %||14.28||Finscreener Ranking||★★★ 50.14|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||★★★+ 54.05|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||★★★★ 58.14|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||66.44||Earnings Rating||Neutral|
|Market Cap||39.02B||Earnings Date||2nd May 2023|
Today's Price Range
5 Year PE Ratio Range
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||2nd May 2023|
|Estimated EPS Next Report||3.32|
|EPS Growth Next 5 Years %||10.00|
|Avg. Weekly Volume||805.53K|
|Avg. Monthly Volume||859.88K|
|Avg. Quarterly Volume||955.29K|
Biogen Inc. (NASDAQ: BIIB) stock closed at 270.03 per share at the end of the most recent trading day (a 1.83% change compared to the prior day closing price) with a volume of 968.18K shares and market capitalization of 39.02B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 9100 people. Biogen Inc. CEO is Michel Vounatsos.
The one-year performance of Biogen Inc. stock is 24.49%, while year-to-date (YTD) performance is -2.49%. BIIB stock has a five-year performance of 3.81%. Its 52-week range is between 187.16 and 311.88, which gives BIIB stock a 52-week price range ratio of 66.44%
Biogen Inc. currently has a PE ratio of 14.20, a price-to-book (PB) ratio of 3.15, a price-to-sale (PS) ratio of 5.19, a price to cashflow ratio of 17.10, a PEG ratio of 2.32, a ROA of 12.73%, a ROC of 16.54% and a ROE of 26.51%. The company’s profit margin is 31.62%, its EBITDA margin is 40.40%, and its revenue ttm is $7.63 Billion , which makes it $52.98 revenue per share.
Of the last four earnings reports from Biogen Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $3.32 for the next earnings report. Biogen Inc.’s next earnings report date is 02nd May 2023.
The consensus rating of Wall Street analysts for Biogen Inc. is Moderate Buy (1.74), with a target price of $308.58, which is +14.28% compared to the current price. The earnings rating for Biogen Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Biogen Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Biogen Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.50, ATR14 : 6.27, CCI20 : 52.73, Chaikin Money Flow : 0.00, MACD : -2.97, Money Flow Index : 47.30, ROC : 2.67, RSI : 51.65, STOCH (14,3) : 91.97, STOCH RSI : 1.00, UO : 54.81, Williams %R : -8.03), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Biogen Inc. in the last 12-months were: Ginger Gregory (Option Excercise at a value of $0), Ginger Gregory (Sold 5 610 shares of value $1 683 617 ), Michael R. Mcdonnell (Option Excercise at a value of $0), Nicole Murphy (Option Excercise at a value of $0), Priya Singhal (Option Excercise at a value of $0), Rachid Izzar (Option Excercise at a value of $0), Robin C. Kramer (Option Excercise at a value of $0), Susan H. Alexander (Option Excercise at a value of $0), Susan H. Alexander (Sold 5 532 shares of value $1 552 832 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Moderate Buy||Moderate Buy||Moderate Buy|
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
CEO: Michel Vounatsos
Telephone: +1 617 679-2000
Address: 225 Binney Street, Cambridge 02142, MA, US
Number of employees: 9 100
Thu, 23 Mar 2023 12:30 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Regeneron (REGN) and Alcon (ALC)- TipRanks. All rights reserved.
Thu, 23 Mar 2023 10:40 GMT Analysts Top Healthcare Picks: Biogen (BIIB), Applied DNA Sciences (APDN)- TipRanks. All rights reserved.
Thu, 23 Mar 2023 10:35 GMT Biogen (BIIB) Receives a Hold from BTIG- TipRanks. All rights reserved.
Tue, 21 Mar 2023 12:50 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Danaher (DHR) and Blueprint Medicines (BPMC)- TipRanks. All rights reserved.
Mon, 20 Mar 2023 23:00 GMT Analysts Conflicted on These Healthcare Names: Biogen (BIIB), Sarepta Therapeutics (SRPT) and G1 Therapeutics (GTHX)- TipRanks. All rights reserved.
Tue, 14 Mar 2023 10:11 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Illumina (ILMN) and Arcutis Biotherapeutics (ARQT)- TipRanks. All rights reserved.
Mon, 13 Mar 2023 18:30 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Crinetics Pharmaceuticals (CRNX) and 89bio (ETNB)- TipRanks. All rights reserved.
Fri, 17 Feb 2023 15:05 GMT Biogen (BIIB) Gets a Buy from SVB Securities- TipRanks. All rights reserved.
Fri, 17 Feb 2023 04:50 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), SAGE Therapeutics (SAGE) and Karyopharm Therapeutics (KPTI)- TipRanks. All rights reserved.
Thu, 16 Feb 2023 16:40 GMT Analysts Offer Insights on Healthcare Companies: Amedisys (AMED), Biogen (BIIB) and Waters (WAT)- TipRanks. All rights reserved.
Thu, 16 Feb 2023 09:55 GMT Biogen (BIIB) Gets a Buy from Morgan Stanley- TipRanks. All rights reserved.
Wed, 15 Feb 2023 13:30 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and ChitogenX (OtherCHNXF)- TipRanks. All rights reserved.
Wed, 15 Feb 2023 13:20 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Applied DNA Sciences (APDN) and Provention Bio (PRVB)- TipRanks. All rights reserved.
Thu, 09 Feb 2023 13:40 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Envista Holdings (NVST)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.